Celgene, a major biotech company, said on Thursday that it planned to stop developing a critical drug. The drug, …
Celgene Corp.'s (NASDAQ: CELG) is arguably one of the globe's most successful biotech companies, yet analysts at investment researcher Morgan Stanley cut their rating on the company from equal weight to underweight on Friday. …
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more. Celgene's past success stemmed primarily from four drugs: Revlimid, Pomalyst, …
As the broader market rallied on Tuesday on the back of hopeful rhetoric around tax reform, the healthcare sector happily participated. The biotechnology subgroup of stocks also flocked higher, leaving plenty of so-called “bullish reversals” …
Celgene Corporation's (NASDAQ:CELG) stock were down more than 5% in premarket trade following news of a drug development disappointment. In after-hours on Thursday, the pharmaceutical firm announced it would not take a …
- ORGS is an Overlooked Cell Therapy Manufacturer and Developer Working with Major Biotech Companies like Servier, CRISPR (CRSP), and Adaptimmune (ADAP), Among Others - Celgene-Juno and Gilead-Kite Deals Demonstrate Just …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full-year …